Top News

FDA Scales Back Domestic Inspections

March 18, 2020

FDA postpones routine domestic facility inspections due to the COVID-19 pandemic.

Thermo Fisher Scientific to Acquire Qiagen for $11.5 Billion

March 05, 2020

The deal is expected to close during the first half of 2021.

Gilead to Acquire Immuno-oncology Company for $4.9 Billion

March 03, 2020

The acquisition will give Gilead access to Forty Seven’s investigational lead product candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of numerous cancers.

Takeda to Divest Non-Core Products to Hypera for $825 Million

March 03, 2020

Under the agreement, Takeda will divest the rights, title, and interest to 18 over-the-counter and prescription products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, and Peru.

FDA Ties First Drug Shortage to Coronavirus Outbreak

February 28, 2020

With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain.

CPhI Japan Rescheduled Amid Novel Coronavirus Outbreak

February 26, 2020

The decision was made after it was determined that many of the event’s largest stakeholders would be unable to travel to the conference due to the novel coronavirus outbreak.

Eli Lilly Completes Acquisition of Dermira for $1.1 Billion

February 20, 2020

Through the agreement, Lilly will expand its immunology pipeline with lebrikizumab, Dermira’s novel, investigational mAb designed to bind interleukin-13 with high affinity.

WuXi Biologics Subsidiary in $3-Billion Vaccine Manufacturing Contract

February 18, 2020

WuXi Vaccines, WuXi Biologics’ joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with a global vaccine leader for $3 billion.

CPhI South East Asia Rescheduled for July 2020

February 17, 2020

Ongoing coronavirus outbreak prompts date change to ensure safety of trade show participants.

WuXi Biologics Provides Update on Operations in Light of Coronavirus Outbreak

February 14, 2020

The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.